


Accepted Manuscript

Title: Mepolizumab use: post-approval academic practice experience

Author: Mariel R. Benjamin, Bruce S. Bochner, Anju T. Peters

PII: S1081-1206(18)30252-7
DOI: <https://doi.org/10.1016/j.anai.2018.04.001>
Reference: ANAI 2518

To appear in: *Annals of Allergy, Asthma & Immunology*



Please cite this article as: Mariel R. Benjamin, Bruce S. Bochner, Anju T. Peters, Mepolizumab use: post-approval academic practice experience, *Annals of Allergy, Asthma & Immunology* (2018), <https://doi.org/10.1016/j.anai.2018.04.001>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Mepolizumab use: post-approval academic practice experience

Authors: Mariel R. Benjamin, MD, Bruce S. Bochner, MD, and Anju T. Peters, MD.

Division of Allergy and Immunology, Department of Medicine, Northwestern University
Feinberg School of Medicine, Chicago, IL USA.

Corresponding author: Anju T. Peters, MD

Division of Allergy and Immunology, Department of Medicine, Northwestern University
Feinberg School of Medicine, 211 E. Ontario, Suite 1000, Chicago, IL 60611, USA.

Tel.: 312-695-4000

Fax: 312-695-4141

Email: anjupeters@northwestern.edu

Conflict of Interest:

Bruce S. Bochner has current or recent consulting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-Aventis, TEVA, AstraZeneca and Allakos, Inc. and owns stock in Allakos. He receives publication-related royalty payments from Elsevier and UpToDate™, and is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University on the potential sales of such products. B.S.B. is also a co-founder of Allakos, Inc. which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies.

Anju T. Peters previously served as a consultant for Sanofi-Regeneron.

Download English Version:

<https://daneshyari.com/en/article/8711696>

Download Persian Version:

<https://daneshyari.com/article/8711696>

[Daneshyari.com](https://daneshyari.com)